Veracyte Net Income
| VCYT Stock | USD 36.73 0.54 1.49% |
As of the 11th of February 2026, Veracyte has the Semi Deviation of 2.82, risk adjusted performance of 0.029, and Coefficient Of Variation of 3855.5. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Veracyte, as well as the relationship between them.
Veracyte Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.2056 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 21.7 M | 22.8 M | |
| Net Income From Continuing Ops | 27.8 M | 29.1 M | |
| Net Loss | -32.9 M | -34.5 M | |
| Net Income Per Share | 0.28 | 0.30 | |
| Net Income Per E B T | 0.84 | 0.77 |
Veracyte | Net Income | Build AI portfolio with Veracyte Stock |
The evolution of Net Income for Veracyte provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Veracyte compares to historical norms and industry peers.
Latest Veracyte's Net Income Growth Pattern
Below is the plot of the Net Income of Veracyte over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Veracyte financial statement analysis. It represents the amount of money remaining after all of Veracyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Veracyte's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Veracyte's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 24.14 M | 10 Years Trend |
|
Net Income |
| Timeline |
Veracyte Net Income Regression Statistics
| Arithmetic Mean | (22,759,905) | |
| Geometric Mean | 27,160,880 | |
| Coefficient Of Variation | (123.40) | |
| Mean Deviation | 19,747,523 | |
| Median | (25,580,000) | |
| Standard Deviation | 28,084,734 | |
| Sample Variance | 788.8T | |
| Range | 99.7M | |
| R-Value | 0.19 | |
| Mean Square Error | 812.4T | |
| R-Squared | 0.03 | |
| Significance | 0.48 | |
| Slope | 1,031,389 | |
| Total Sum of Squares | 12620T |
Veracyte Net Income History
Other Fundumenentals of Veracyte
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Veracyte Net Income component correlations
Veracyte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Veracyte is extremely important. It helps to project a fair market value of Veracyte Stock properly, considering its historical fundamentals such as Net Income. Since Veracyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Veracyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Veracyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Veracyte introduce new products? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.263 | Earnings Share 0.38 | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Veracyte's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Veracyte 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Veracyte's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Veracyte.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Veracyte on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Veracyte or generate 0.0% return on investment in Veracyte over 90 days. Veracyte is related to or competes with Kiniksa Pharmaceuticals, Zai Lab, Legend Biotech, Scholar Rock, Disc Medicine, Tarsus Pharmaceuticals, and Ideaya Biosciences. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with i... More
Veracyte Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Veracyte's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Veracyte upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.91 | |||
| Information Ratio | 0.0053 | |||
| Maximum Drawdown | 36.91 | |||
| Value At Risk | (4.35) | |||
| Potential Upside | 5.74 |
Veracyte Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Veracyte's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Veracyte's standard deviation. In reality, there are many statistical measures that can use Veracyte historical prices to predict the future Veracyte's volatility.| Risk Adjusted Performance | 0.029 | |||
| Jensen Alpha | 0.1331 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | 0.0082 | |||
| Treynor Ratio | (0.33) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Veracyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Veracyte February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.029 | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 2.61 | |||
| Semi Deviation | 2.82 | |||
| Downside Deviation | 2.91 | |||
| Coefficient Of Variation | 3855.5 | |||
| Standard Deviation | 4.5 | |||
| Variance | 20.22 | |||
| Information Ratio | 0.0053 | |||
| Jensen Alpha | 0.1331 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | 0.0082 | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 36.91 | |||
| Value At Risk | (4.35) | |||
| Potential Upside | 5.74 | |||
| Downside Variance | 8.49 | |||
| Semi Variance | 7.94 | |||
| Expected Short fall | (3.30) | |||
| Skewness | 3.45 | |||
| Kurtosis | 20.75 |
Veracyte Backtested Returns
Veracyte owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0371, which indicates the firm had a -0.0371 % return per unit of risk over the last 3 months. Veracyte exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Veracyte's Risk Adjusted Performance of 0.029, semi deviation of 2.82, and Coefficient Of Variation of 3855.5 to confirm the risk estimate we provide. The entity has a beta of -0.32, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Veracyte are expected to decrease at a much lower rate. During the bear market, Veracyte is likely to outperform the market. At this point, Veracyte has a negative expected return of -0.1%. Please make sure to validate Veracyte's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Veracyte performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.14 |
Insignificant predictability
Veracyte has insignificant predictability. Overlapping area represents the amount of predictability between Veracyte time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Veracyte price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Veracyte price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 8.32 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Veracyte Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Veracyte reported net income of 24.14 M. This is 92.93% lower than that of the Biotechnology sector and 65.54% lower than that of the Health Care industry. The net income for all United States stocks is 95.77% higher than that of the company.
Veracyte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veracyte's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Veracyte could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics of similar companies.Veracyte is currently under evaluation in net income category among its peers.
Veracyte Current Valuation Drivers
We derive many important indicators used in calculating different scores of Veracyte from analyzing Veracyte's financial statements. These drivers represent accounts that assess Veracyte's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Veracyte's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.8B | 1.7B | 2.0B | 3.0B | 2.7B | 2.9B | |
| Enterprise Value | 2.6B | 1.6B | 1.8B | 2.8B | 2.6B | 2.7B |
Veracyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Veracyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Veracyte's managers, analysts, and investors.Environmental | Governance | Social |
Veracyte Institutional Holders
Institutional Holdings refers to the ownership stake in Veracyte that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Veracyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Veracyte's value.| Shares | Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 1.6 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Bank Of America Corp | 2025-06-30 | 1.5 M | Gw&k Investment Management, Llc | 2025-06-30 | 1.4 M | First Trust Advisors L.p. | 2025-06-30 | 1.1 M | Qube Research & Technologies | 2025-06-30 | 983.8 K | Northern Trust Corp | 2025-06-30 | 970.5 K | Squarepoint Ops Llc | 2025-06-30 | 897.4 K | Bamco Inc | 877.2 K | Fmr Inc | 2025-06-30 | 8.1 M | Vanguard Group Inc | 2025-06-30 | 8.1 M |
Veracyte Fundamentals
| Return On Equity | 0.0249 | ||||
| Return On Asset | 0.0243 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 2.6 B | ||||
| Shares Outstanding | 79.05 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 99.59 % | ||||
| Number Of Shares Shorted | 5.18 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 5.91 X | ||||
| Revenue | 445.76 M | ||||
| Gross Profit | 349.6 M | ||||
| EBITDA | 49.2 M | ||||
| Net Income | 24.14 M | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 50.74 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.09 X | ||||
| Book Value Per Share | 15.91 X | ||||
| Cash Flow From Operations | 75.1 M | ||||
| Short Ratio | 7.56 X | ||||
| Earnings Per Share | 0.38 X | ||||
| Target Price | 47.67 | ||||
| Number Of Employees | 824 | ||||
| Beta | 1.91 | ||||
| Market Capitalization | 2.93 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (443.98 M) | ||||
| Working Capital | 293.63 M | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
| Net Asset | 1.3 B |
About Veracyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veracyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veracyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veracyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.